| Literature DB >> 25366076 |
Jae Yeon Seok1, Myunghee Kang1, Jungsuk An1, Hyunchul Kim1, Kwang-Beom Lee2, Hyun Yee Cho1.
Abstract
Entities:
Year: 2014 PMID: 25366076 PMCID: PMC4215966 DOI: 10.4132/KoreanJPathol.2014.48.5.382
Source DB: PubMed Journal: Korean J Pathol ISSN: 1738-1843
Fig. 1.An ill-defined solid yellow-tan mass is noted in the fallopian tube wall. Grossly, the mass abuts the lumen of the fallopian tube.
Fig. 2.Low-power view of papillary cystadenoma shows an expansile growth pushing the lumen of the fallopian tube and blunting the plicae of the fallopian tube (lower left) (A). The tumor has many small cystic spaces containing papillary projections with glomeruloid features in some areas (B). The papillary fronds have monolayered cuboidal/columnar epithelium showing clear cytoplasm and a distinct cell border. The fibrovascular core contains a compact capillary network (C). Tumor cells with eosinophilic cytoplasm do not have cilia compared to ciliated tubal epithelial cells (lower left) (D).
Fig. 3.Immunohistochemically, the tumor cells show positivity for Cam5.2 (A), cytokeratin 7 (CK7) (B), vimentin (C), and CD10 (D). In contrast, the epithelial cells of the fallopian tube (lower left) show strong positivity for Cam5.2 and vimentin, variable positivity for CK7, and negativity for CD10.
Clinical features of papillary cystadenoma in the female genital tract
| Case No. | Year | Age (yr) | Site | Side | Size (cm) | Symptom | History of VHL | VHL | Other |
|---|---|---|---|---|---|---|---|---|---|
| 1[ | 1988 | 46 | MS | Lt | 3 | None | P (20 yr) | ReA, RCC,K/L/P cyst | Fimbrial adhesion |
| 2 | 1989 | 46 | BL | Lt | 3 | Mass | P (25 yr) | - | - |
| 3 | 1990 | 35 | BL | Rt | 5 | Pain | A | CbH, RCC,K/P cyst | - |
| 4[ | 1994 | 20 | BL | Rt | 4 | Nausea | A | CbH, RCC,ELST, K/P cyst | - |
| 5[ | 2005 | 32 | MS | NA | NA | NA | P | RCC | - |
| 6[ | 2005 | NA | MS | NA | NA | NA | A | - | Misdiagnosis (serous borderline tumor) |
| 7 | 2010 | 23 | MS | Rt | 3.5 | Pain | P (5 yr) | SpH | - |
| 8[ | 2012 | 52 | MS | Lt | 6 | Pain | N | - | Omental implant Misdiagnosis (malignant serous tumor) |
| 9[ | 2012 | 35 | BL | NA | 3.5 | None | P | - | - |
| 10[ | 2012 | 34 | MS | Rt | 5.5 | None | A | - | - |
| 11[ | 2012 | 24 | MS | Lt | 5 | None | A | - | - |
| 12[ | 2012 | 36 | MS | Bilat | Rt 5.2, Lt 3 | None | P | - | - |
| 13[ | 2012 | 47 | BL | Lt | 6.5 | None | P | CbH | Adhesion to rectum |
| 14[ | 2012 | 56 | PD | 6 | Pain | N | - | - | |
| 15 | Present case | 44 | MS | Lt | 3.9 | None | N | K/L cyst | Fallopian tube involvement |
VHL, von Hippel-Lindau disease; MS, mesosalpinx; Lt, left; P, previous history of VHL; ReA, retinal angioma; RCC, renal cell carcinoma; K/L/P, kidney/liver/pancreas; BL, broad ligament; Rt, right; A, VHL detected after the diagnosis of papillary cystadenoma; CbH, cerebellar hemangioblastoma; ELST, endolymphatic sac tumor; NA, not available; SpH, spinal cord hemangioblastoma; N, no previous history and no further detection of VHL after the diagnosis of papillary cystadenoma; Bilat, bilateral; PD, pouch of Douglas.
Immunohistochemical findings of papillary cystadenoma in the female genital tract
| Marker | Present case | 14 Reported cases | Positive rate (%) |
|---|---|---|---|
| CK7 | + | 10/10 | 100 |
| Cam5.2 | + | 6/6 | 100 |
| HMW-CK | + | 1/1 | 100 |
| CK | ND | 5/5 | 100 |
| CK19 | + | 1/1 | 100 |
| CK20 | ND | 0/4 | 0 |
| Ber-EP4 | ND | 3/3 | 100 |
| EMA | + | 9/11 | 81.8 |
| Vimentin | + | 8/9 | 88.9 |
| CD10 | + | 9/10 | 90 |
| α-Inhibin | – | 0/3 | 0 |
| Calretinin | – | 3/8 | 37.5 |
| AMACR | – | 0/11 | 0 |
| HMB45 | – | 0/1 | 0 |
| c-kit | – | 0/1 | 0 |
| PAX2 | ND | 5/5 | 100 |
| RCC marker | ND | 1/9 | 11.1 |
| VHL40 | ND | 3/5 | 60 |
| CA125 | ND | 5/7 | 71.4 |
| WT-1 | ND | 4/7 | 57.1 |
| HBME-1 | ND | 2/5 | 40 |
| CEA | ND | 0/3 | 0 |
| ER | ND | 0/2 | 0 |
| PR | ND | 0/2 | 0 |
| AR | ND | 2/7 | 28.6 |
28.6CK, cytokeratin; HMW-CK, high-molecular weight cytokeratin; ND, not done; EMA, epithelial membrane antigen; AMACR, α-methylacyl coenzyme A racemase; HMB45, human melanoma black 45; RCC, renal cell carcinoma; VHL40, von Hippel-Lindau 40; CA125, cancer antigen 125; WT-1, Wilms tumour-1; CEA, carcinoembryonic antigen; ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor.